Trevi Therapeutics (TRVI) Stock Analysis

What Trevi Therapeutics does

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

Key metrics

ETFs linked to TRVI

Broad-market and Healthcare sector ETFs an investor holding Trevi Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how TRVI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Trevi Therapeutics?

Trevi Therapeutics trades under the ticker TRVI on NASDAQ.

Which exchange is TRVI listed on?

TRVI is listed on NASDAQ.

What sector does Trevi Therapeutics operate in?

Trevi Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TRVI in a portfolio?

PortView shows TRVI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.